A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Open Access
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 16 (1) , 38-44
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 28 references indexed in Scilit:
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831Journal of Clinical Oncology, 2014
- Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancerAsia-Pacific Journal of Clinical Oncology, 2014
- A Systematic Review of Vinorelbine for the Treatment of Breast CancerThe Breast Journal, 2013
- Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2British Journal of Cancer, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001